JP2010518006A5 - - Google Patents

Download PDF

Info

Publication number
JP2010518006A5
JP2010518006A5 JP2009548327A JP2009548327A JP2010518006A5 JP 2010518006 A5 JP2010518006 A5 JP 2010518006A5 JP 2009548327 A JP2009548327 A JP 2009548327A JP 2009548327 A JP2009548327 A JP 2009548327A JP 2010518006 A5 JP2010518006 A5 JP 2010518006A5
Authority
JP
Japan
Prior art keywords
actriia
composition
activin
amino acid
breast cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2009548327A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010518006A (ja
JP5237970B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2008/001429 external-priority patent/WO2008094708A2/en
Publication of JP2010518006A publication Critical patent/JP2010518006A/ja
Publication of JP2010518006A5 publication Critical patent/JP2010518006A5/ja
Application granted granted Critical
Publication of JP5237970B2 publication Critical patent/JP5237970B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2009548327A 2007-02-01 2008-02-01 乳癌を治療または予防するためのアクチビンActRIIaアンタゴニストおよび使用 Active JP5237970B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US89907007P 2007-02-01 2007-02-01
US60/899,070 2007-02-01
US54007P 2007-10-25 2007-10-25
US61/000,540 2007-10-25
PCT/US2008/001429 WO2008094708A2 (en) 2007-02-01 2008-02-01 Activin-actriia antagonists and uses for treating or preventing breast cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2013073352A Division JP6243133B2 (ja) 2007-02-01 2013-03-29 乳癌を治療または予防するためのアクチビンActRIIaアンタゴニストおよび使用

Publications (3)

Publication Number Publication Date
JP2010518006A JP2010518006A (ja) 2010-05-27
JP2010518006A5 true JP2010518006A5 (OSRAM) 2012-03-15
JP5237970B2 JP5237970B2 (ja) 2013-07-17

Family

ID=39386169

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2009548327A Active JP5237970B2 (ja) 2007-02-01 2008-02-01 乳癌を治療または予防するためのアクチビンActRIIaアンタゴニストおよび使用
JP2013073352A Active JP6243133B2 (ja) 2007-02-01 2013-03-29 乳癌を治療または予防するためのアクチビンActRIIaアンタゴニストおよび使用
JP2014209681A Withdrawn JP2015025005A (ja) 2007-02-01 2014-10-14 乳癌を治療または予防するためのアクチビンActRIIaアンタゴニストおよび使用
JP2016215914A Pending JP2017031217A (ja) 2007-02-01 2016-11-04 乳癌を治療または予防するためのアクチビンActRIIaアンタゴニストおよび使用

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2013073352A Active JP6243133B2 (ja) 2007-02-01 2013-03-29 乳癌を治療または予防するためのアクチビンActRIIaアンタゴニストおよび使用
JP2014209681A Withdrawn JP2015025005A (ja) 2007-02-01 2014-10-14 乳癌を治療または予防するためのアクチビンActRIIaアンタゴニストおよび使用
JP2016215914A Pending JP2017031217A (ja) 2007-02-01 2016-11-04 乳癌を治療または予防するためのアクチビンActRIIaアンタゴニストおよび使用

Country Status (16)

Country Link
US (2) US9526759B2 (OSRAM)
EP (2) EP2111229B1 (OSRAM)
JP (4) JP5237970B2 (OSRAM)
KR (2) KR20140137463A (OSRAM)
CN (3) CN101835485B (OSRAM)
AU (1) AU2008211007B2 (OSRAM)
BR (1) BRPI0806861A2 (OSRAM)
CA (1) CA2677007A1 (OSRAM)
ES (1) ES2415666T3 (OSRAM)
HK (1) HK1199833A1 (OSRAM)
IL (3) IL200186A (OSRAM)
MX (2) MX354099B (OSRAM)
RU (2) RU2473362C2 (OSRAM)
TR (1) TR200906131T1 (OSRAM)
TW (3) TW201716081A (OSRAM)
WO (1) WO2008094708A2 (OSRAM)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3059245B1 (en) * 2004-07-23 2018-11-07 Acceleron Pharma Inc. Actrii receptor antagonistic antibodies
US8128933B2 (en) 2005-11-23 2012-03-06 Acceleron Pharma, Inc. Method of promoting bone growth by an anti-activin B antibody
MX2008006626A (es) 2005-11-23 2008-09-24 Acceleron Pharma Inc Antagonistas de activin-actriia y usos para promover el crecimiento de huesos.
US20100028332A1 (en) * 2006-12-18 2010-02-04 Acceleron Pharma Inc. Antagonists of actriib and uses for increasing red blood cell levels
US8895016B2 (en) 2006-12-18 2014-11-25 Acceleron Pharma, Inc. Antagonists of activin-actriia and uses for increasing red blood cell levels
PL2124999T3 (pl) * 2006-12-18 2013-03-29 Acceleron Pharma Inc Antagoniści aktywiny-actrii i zastosowania do leczenia niedokrwistości
WO2008094708A2 (en) 2007-02-01 2008-08-07 Acceleron Pharma Inc. Activin-actriia antagonists and uses for treating or preventing breast cancer
TWI782836B (zh) * 2007-02-02 2022-11-01 美商艾瑟勒朗法瑪公司 衍生自ActRIIB的變體與其用途
TWI606062B (zh) 2007-02-09 2017-11-21 艾瑟勒朗法瑪公司 包含ActRIIa-Fc融合蛋白的醫藥組合物;ActRIIa-Fc融合蛋白於治療或預防與癌症相關的骨質流失之用途;ActRIIa-Fc融合蛋白於治療或預防多發性骨髓瘤之用途
WO2009038745A1 (en) * 2007-09-18 2009-03-26 Acceleron Pharma Inc. Activin-actriia antagonists and uses for decreasing or inhibiting fsh secretion
CA2729096C (en) 2008-06-26 2020-04-28 Acceleron Pharma Inc. Methods for dosing an actriib antagonist and monitoring of treated patients
HRP20191109T1 (hr) 2008-08-14 2019-09-20 Acceleron Pharma Inc. Gdf klopke za uporabu u liječenju anemije
US8216997B2 (en) 2008-08-14 2012-07-10 Acceleron Pharma, Inc. Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators
WO2010083034A1 (en) * 2009-01-13 2010-07-22 Acceleron Pharma Inc. Methods for increasing adiponectin
AU2010258931B2 (en) * 2009-06-08 2015-04-23 Acceleron Pharma Inc. Methods for increasing thermogenic adipocytes
CN107267520A (zh) 2009-06-12 2017-10-20 阿塞勒隆制药公司 截短的actriib‑fc融合蛋白
ES2869580T3 (es) * 2009-09-09 2021-10-25 Acceleron Pharma Inc Antagonistas de ActRIIB y dosificación y usos de los mismos para tratar obesidad o diabetes tipo 2 regulando el contenido de grasa corporal
EP3260130B1 (en) * 2009-11-03 2021-03-10 Acceleron Pharma Inc. Methods for treating fatty liver disease
CA2781152A1 (en) 2009-11-17 2011-05-26 Acceleron Pharma Inc. Actriib proteins and variants and uses therefore relating to utrophin induction for muscular dystrophy therapy
JP2014502260A (ja) 2010-11-08 2014-01-30 アクセルロン ファーマ, インコーポレイテッド Actriia結合剤およびその使用
US9809636B2 (en) 2012-04-06 2017-11-07 Acceleron Pharma Inc. Methods for increasing red blood cell levels comprising administering BMP9
ES2884095T3 (es) 2012-11-02 2021-12-10 Celgene Corp Antagonistas de activina-actrii y usos para el tratamiento de trastornos óseos y otros trastornos
US20150361163A1 (en) 2014-04-18 2015-12-17 Acceleron Pharma, Inc. Methods for increasing red blood cell levels and treating sickle-cell disease
MA40008A (fr) 2014-06-13 2021-05-05 Acceleron Pharma Inc Antagoniste actrii pour le traitement et la prevention d'un ulcere cutane chez un sujet ayant l'anemie
GB201411320D0 (en) * 2014-06-25 2014-08-06 Ucb Biopharma Sprl Antibody construct
MA41052A (fr) 2014-10-09 2017-08-15 Celgene Corp Traitement d'une maladie cardiovasculaire à l'aide de pièges de ligands d'actrii
MA41119A (fr) * 2014-12-03 2017-10-10 Acceleron Pharma Inc Méthodes de traitement de syndromes myélodysplasiques et d'anémie sidéroblastique
AU2015358469B2 (en) 2014-12-03 2021-05-27 Acceleron Pharma Inc. Activin-ActRII antagonists and uses for treating anemia
CN107849114B (zh) * 2015-04-06 2021-08-20 阿塞勒隆制药公司 单臂i型和ii型受体融合蛋白和其用途
JP2018522579A (ja) 2015-05-20 2018-08-16 セルジーン コーポレイション アクチビンII型受容体リガンドトラップを使用するβ−サラセミアのインビトロ細胞培養法
US20170240639A1 (en) * 2016-02-22 2017-08-24 Acceleron Pharma Inc. Actrii antagonists for use in increasing immune activity
PL3426680T3 (pl) 2016-03-10 2025-03-31 Acceleron Pharma Inc. Białka wiążące receptor aktywiny typu 2 i ich zastosowania
HUE054228T2 (hu) 2016-07-15 2021-08-30 Acceleron Pharma Inc Használható actriia polipeptideket tartalmazó összetételek a pulmonalis hypertónia kezelésében történõ alkalmazásra
PL3490582T3 (pl) 2016-07-27 2024-09-23 Acceleron Pharma Inc. Kompozycje do zastosowania w leczeniu mielofibrozy
WO2018089715A1 (en) 2016-11-10 2018-05-17 Keros Therapeutics, Inc. Activin receptor type iia variants and methods of use thereof
CA3051696A1 (en) * 2017-02-01 2018-08-09 Acceleron Pharma Inc. Tgf.beta. and actrii antagonists for use in increasing immune activity
WO2018183376A1 (en) 2017-03-28 2018-10-04 Rigel Pharmaceuticals, Inc. Acvr2a-specific antibody and method of use thereof
JP7258021B2 (ja) * 2017-11-09 2023-04-14 ケロス セラピューティクス インコーポレイテッド アクチビンIIa型受容体変異体を含む医薬組成物
IL320014A (en) 2018-01-12 2025-06-01 Keros Therapeutics Inc Activin receptor type iib variants and methods of use thereof
CN112601538B (zh) 2018-05-09 2025-08-19 科乐斯疗法公司 激活素受体iia型变体及其使用方法
JP2022549506A (ja) 2019-09-27 2022-11-25 ディスク・メディシン・インコーポレイテッド 骨髄線維症および関連状態を処置するための方法
EP4121088A4 (en) 2020-03-20 2024-07-03 Keros Therapeutics, Inc. Methods of using activin receptor type iib variants
EP4149548A4 (en) 2020-05-13 2024-05-08 Disc Medicine, Inc. ANTI-HEMOJUVELIN ANTIBODIES (HJV) FOR THE TREATMENT OF MYELOFIBROSIS
US12186370B1 (en) 2020-11-05 2025-01-07 Celgene Corporation ACTRIIB ligand trap compositions and uses thereof

Family Cites Families (221)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0637520B2 (ja) 1985-07-03 1994-05-18 味の素株式会社 ポリペプチド
US4973577A (en) 1986-04-04 1990-11-27 The Salk Institute For Biological Studies FSH-releasing peptides
US5092885A (en) 1987-02-12 1992-03-03 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Peptides with laminin activity
US5080891A (en) 1987-08-03 1992-01-14 Ddi Pharmaceuticals, Inc. Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5198346A (en) 1989-01-06 1993-03-30 Protein Engineering Corp. Generation and selection of novel DNA-binding proteins and polypeptides
US5096815A (en) 1989-01-06 1992-03-17 Protein Engineering Corporation Generation and selection of novel dna-binding proteins and polypeptides
US5112946A (en) 1989-07-06 1992-05-12 Repligen Corporation Modified pf4 compositions and methods of use
US5192744A (en) 1990-01-12 1993-03-09 Northwestern University Method of inhibiting angiogenesis of tumors
DE69114782T2 (de) 1990-08-08 1996-04-18 Takeda Chemical Industries Ltd Intravaskulär embolisierendes Mittel mit Gehalt an einem die Angiogenesis hemmenden Stoff.
WO1992004913A1 (en) 1990-09-13 1992-04-02 Children's Hospital Medical Center Of Northern California Method for increasing red blood cell production by treatment with activin or activin-related peptides
AU1411992A (en) 1991-01-15 1992-08-27 Robert A Bok A composition containing a tetracycline and use for inhibiting angiogenesis
US5118667A (en) 1991-05-03 1992-06-02 Celtrix Pharmaceuticals, Inc. Bone growth factors and inhibitors of bone resorption for promoting bone formation
US20050186593A1 (en) 1991-05-10 2005-08-25 The Salk Institute For Biological Studies Cloning and recombinant production of CRF receptor(s)
AU654724B2 (en) 1991-05-10 1994-11-17 Salk Institute For Biological Studies, The Cloning and recombinant production of receptor(s) of the activin/TGF-beta superfamily
US5885794A (en) 1991-05-10 1999-03-23 The Salk Institute For Biological Studies Recombinant production of vertebrate activin receptor polypeptides and identification of receptor DNAs in the activin/TGF-β superfamily
US6162896A (en) 1991-05-10 2000-12-19 The Salk Institute For Biological Studies Recombinant vertebrate activin receptors
US5661007A (en) 1991-06-25 1997-08-26 Genetics Institute, Inc. Bone morphogenetic protein-9 compositions
US6287816B1 (en) 1991-06-25 2001-09-11 Genetics Institute, Inc. BMP-9 compositions
US6692925B1 (en) * 1992-11-17 2004-02-17 Ludwig Institute For Cancer Research Proteins having serine/threonine kinase domains, corresponding nucleic acid molecules, and their use
WO1994015965A1 (en) 1993-01-12 1994-07-21 Johns Hopkins University School Of Medicine Growth differentiation factor-3
US6228879B1 (en) 1997-10-16 2001-05-08 The Children's Medical Center Methods and compositions for inhibition of angiogenesis
EP0698095B1 (en) 1993-05-12 2004-04-28 Genetics Institute, LLC Bmp-10 compositions
US5637480A (en) 1993-05-12 1997-06-10 Genetics Institute, Inc. DNA molecules encoding bone morphogenetic protein-10
US5677196A (en) 1993-05-18 1997-10-14 University Of Utah Research Foundation Apparatus and methods for multi-analyte homogeneous fluoro-immunoassays
US5831050A (en) 1993-06-07 1998-11-03 Creative Biomolecules, Inc. Morphogen cell surface receptor
AU701623B2 (en) 1993-10-14 1999-02-04 President And Fellows Of Harvard College Method of inducing and maintaining neuronal cells
US5525490A (en) 1994-03-29 1996-06-11 Onyx Pharmaceuticals, Inc. Reverse two-hybrid method
US5837682A (en) 1996-03-08 1998-11-17 The Children's Medical Center Corporation Angiostatin fragments and method of use
US5658876A (en) 1994-04-28 1997-08-19 The General Hospital Corporation Activin antagonists as novel contraceptives
US5760010A (en) 1995-01-01 1998-06-02 Klein; Ira Method of treating liver disorders with a macrolide antibiotic
US5814565A (en) 1995-02-23 1998-09-29 University Of Utah Research Foundation Integrated optic waveguide immunosensor
DE69636866D1 (en) 1995-04-11 2007-03-15 Gen Hospital Corp Reverse "two-hybrid"-systeme
ES2206602T3 (es) 1995-10-23 2004-05-16 The Children's Medical Center Corporation Compuestos y metodos terapeuticos inhibidores de angiogenesis.
US6132988A (en) 1995-10-27 2000-10-17 Takeda Chemical Industries, Ltd. DNA encoding a neuronal cell-specific receptor protein
GB9526131D0 (en) 1995-12-21 1996-02-21 Celltech Therapeutics Ltd Recombinant chimeric receptors
US6465431B1 (en) 1999-11-17 2002-10-15 Boston Life Sciences, Inc. Pharmaceutical compositions comprising troponin subunits, fragments and homologs thereof and methods of their use to inhibit angiogenesis
US20050244867A1 (en) 1996-03-26 2005-11-03 Human Genome Sciences, Inc. Growth factor HTTER36
US6004780A (en) 1996-03-26 1999-12-21 Human Genome Sciences, Inc. Growth factor HTTER36
RU2194528C2 (ru) 1996-05-31 2002-12-20 Дзе Скриппс Рисерч Инститьют Способы и композиции, используемые для ингибирования ангиогенеза
NZ334546A (en) 1996-10-25 2000-12-22 G Erythropoietin receptor agonist and use in the treatment of hematopoietic disorders
US6573256B2 (en) 1996-12-30 2003-06-03 Bone Care International, Inc. Method of inhibiting angiogenesis using active vitamin D analogues
US6605699B1 (en) 1997-01-21 2003-08-12 Human Genome Sciences, Inc. Galectin-11 polypeptides
US6034062A (en) 1997-03-13 2000-03-07 Genetics Institute, Inc. Bone morphogenetic protein (BMP)-9 compositions and their uses
US6231880B1 (en) 1997-05-30 2001-05-15 Susan P. Perrine Compositions and administration of compositions for the treatment of blood disorders
US6656475B1 (en) 1997-08-01 2003-12-02 The Johns Hopkins University School Of Medicine Growth differentiation factor receptors, agonists and antagonists thereof, and methods of using same
US6891082B2 (en) 1997-08-01 2005-05-10 The Johns Hopkins University School Of Medicine Transgenic non-human animals expressing a truncated activintype II receptor
AU8666398A (en) 1997-08-01 1999-02-22 Johns Hopkins University School Of Medicine, The Methods to identify growth differentiation factor (gdf) receptors
US6696260B1 (en) 1997-08-01 2004-02-24 The Johns Hopkins University School Of Medicine Methods to identify growth differentiation factor (GDF) binding proteins
WO1999010364A1 (en) 1997-08-29 1999-03-04 Human Genome Sciences, Inc. Follistatin-3
US6953662B2 (en) 1997-08-29 2005-10-11 Human Genome Sciences, Inc. Follistatin-3
ATE373712T1 (de) 1997-10-03 2007-10-15 Chugai Pharmaceutical Co Ltd Natürlicher menschlicher antikörper
US6475784B1 (en) 1997-11-14 2002-11-05 Valentis, Inc. Inhibition of angiogenesis by delivery of nucleic acids encoding anti-angiogenic polypeptides
AU1690399A (en) 1997-12-26 1999-07-19 Mochida Pharmaceutical Co., Ltd. Neovascularization inhibitor containing dienogest as the active ingredient
US6696411B1 (en) 1998-04-22 2004-02-24 Cornell Research Foundation, Inc. Canine erythropoietin gene and recombinant protein
US6482802B1 (en) 1998-05-11 2002-11-19 Endowment For Research In Human Biology, Inc. Use of neomycin for treating angiogenesis-related diseases
US6413513B1 (en) 1998-05-22 2002-07-02 Entremed, Inc. Compositions and methods for inhibiting endothelial cell proliferation and regulating angiogenesis using cancer markers
US6395718B1 (en) 1998-07-06 2002-05-28 Guilford Pharmaceuticals Inc. Pharmaceutical compositions and methods of inhibiting angiogenesis using naaladase inhibitors
JP2002530273A (ja) 1998-07-13 2002-09-17 パーカシュ エス. ギル, 脈管形成および腫瘍増殖の新規インヒビター
JP2002520367A (ja) 1998-07-14 2002-07-09 ブリストル−マイヤーズ スクイブ カンパニー アンギオスタチンのリジン結合フラグメント
EP1119252A4 (en) 1998-08-21 2004-03-03 Childrens Medical Center USE OF MELANIN FOR INHIBITING ANGIOGENESIS AND MACULAR DEGENERATION
AU765584B2 (en) 1998-09-17 2003-09-25 Eli Lilly And Company Protein formulations
CA2343715C (en) 1998-09-22 2004-05-18 Long Yu New human growth differentiation factor encoding sequence and polypeptide encoded by such dna sequence and producing method thereof
US6472179B2 (en) 1998-09-25 2002-10-29 Regeneron Pharmaceuticals, Inc. Receptor based antagonists and methods of making and using
US6548634B1 (en) 1998-09-30 2003-04-15 Chiron Corporation Synthetic peptides having FGF receptor affinity
US6238860B1 (en) 1998-11-05 2001-05-29 Dyax Corp. Binding moieties for human parvovirus B19
US6777205B1 (en) 1998-11-06 2004-08-17 Sterrenbeld Biotechnologie North America, Inc. Host cells expressing recombinant human erythropoietin
US20040009535A1 (en) 1998-11-27 2004-01-15 Celltech R&D, Inc. Compositions and methods for increasing bone mineralization
CA2359242C (en) 1999-01-21 2009-12-08 Metamorphix, Inc. Growth differentiation factor inhibitors and uses therefor
US6914128B1 (en) 1999-03-25 2005-07-05 Abbott Gmbh & Co. Kg Human antibodies that bind human IL-12 and methods for producing
WO2000062809A1 (en) * 1999-04-19 2000-10-26 Kyowa Hakko Kogyo Co., Ltd. Proliferation inhibitor for androgen-independent tumor
US6468543B1 (en) 1999-05-03 2002-10-22 Zymogenetics, Inc. Methods for promoting growth of bone using ZVEGF4
KR20020065517A (ko) 1999-11-12 2002-08-13 맥시겐 홀딩스 리미티드 인터페론 감마 접합체
CA2394576A1 (en) 1999-12-15 2001-06-21 Research Development Foundation Betaglycan as an inhibin receptor and uses thereof
AU2291001A (en) 1999-12-23 2001-07-03 Emory University Chalcone and its analogs as agents for the inhibition of angiogenesis and related disease states
US20030224501A1 (en) 2000-03-17 2003-12-04 Young Paul E. Bone morphogenic protein polynucleotides, polypeptides, and antibodies
US20050019826A1 (en) 2000-03-31 2005-01-27 Roselyne Tournaire Peptides blocking vascular endothelial growth factor(vegf)-mediated angiogenesis, polynucleotides encoding said pepetides and methods of use thereof
JP4487376B2 (ja) 2000-03-31 2010-06-23 味の素株式会社 腎疾患治療剤
US6627424B1 (en) 2000-05-26 2003-09-30 Mj Bioworks, Inc. Nucleic acid modifying enzymes
AU2001269709A1 (en) 2000-07-19 2002-02-05 Eli Lilly And Company Nucleic acids, vectors, host cells, polypeptides, and uses thereof
US6632180B1 (en) 2000-09-07 2003-10-14 John H. Laragh Method for evaluating and treating hypertension
DE10045591A1 (de) 2000-09-15 2002-04-04 Klaus Pfizenmaier Ortsspezifische, antikörpervermittelte Aktivierung proapoptotischer Zytokine - AMAIZe (Antibody-Mediated Apoptosis Inducing Zytokine)
WO2002032925A2 (en) 2000-10-16 2002-04-25 Phylos, Inc. Protein scaffolds for antibody mimics and other binding proteins
US7087224B2 (en) 2000-10-31 2006-08-08 Amgen Inc. Method of treating anemia by administering IL-1ra
US6548477B1 (en) 2000-11-01 2003-04-15 Praecis Pharmaceuticals Inc. Therapeutic agents and methods of use thereof for the modulation of angiogenesis
EP1345959B1 (en) 2000-11-20 2011-05-25 The Board Of Trustees Of The University Of Illinois Membrane scaffold proteins
US20030082233A1 (en) 2000-12-01 2003-05-01 Lyons Karen M. Method and composition for modulating bone growth
AU2002236558A1 (en) 2000-12-01 2002-06-11 Regents Of The University Of California Method and composition for modulating bone growth
TW200526779A (en) 2001-02-08 2005-08-16 Wyeth Corp Modified and stabilized GDF propeptides and uses thereof
US20040132675A1 (en) 2002-02-08 2004-07-08 Calvin Kuo Method for treating cancer and increasing hematocrit levels
US7294472B2 (en) 2001-03-14 2007-11-13 Caden Biosciences Method for identifying modulators of G protein coupled receptor signaling
US20040121008A1 (en) 2001-03-16 2004-06-24 Keiko Shiraishi Process for producing sustained release preparation
DK1390535T3 (da) 2001-04-26 2010-12-06 Amgen Mountain View Inc Kombinatoriske biblioteker af monomer-domæner
PL403488A1 (pl) 2001-05-24 2013-07-08 Zymogenetics, Inc. Zastosowanie bialka fuzyjnego TACI-immunoglobulina, bialko fuzyjne, czasteczka kwasu nukleinowego kodujaca bialko fuzyjne, kompozycja farmaceutyczna i sposób wytwarzania bialka fuzyjnego TACI-immunoglobulina
US7074901B2 (en) 2001-05-25 2006-07-11 Serono Genetics Institute S.A. Isolated human vCOL16A1 polypeptide and fragments thereof
AUPR638101A0 (en) 2001-07-13 2001-08-09 Bioa Pty Limited Composition and method for treatment of disease
US6855344B2 (en) 2001-07-17 2005-02-15 Integrated Chinese Medicine Holdings, Ltd. Compositions and methods for prostate and kidney health and disorders, an herbal preparation
CA2452246A1 (en) 2001-07-17 2003-01-30 Teijin Limited Method of screening substance by measuring ppar .delta. activating effect and agent
KR100453877B1 (ko) 2001-07-26 2004-10-20 메덱스젠 주식회사 연쇄체화에 의한 면역 글로블린 융합 단백질의 제조 방법 및 이 방법에 의해 제조된 TNFR/Fc 융합 단백질, 상기 단백질을 코딩하는 DNA, 상기 DNA를 포함하는벡터, 및 상기 벡터에 의한 형질전환체
US7320789B2 (en) 2001-09-26 2008-01-22 Wyeth Antibody inhibitors of GDF-8 and uses thereof
US6784154B2 (en) 2001-11-01 2004-08-31 University Of Utah Research Foundation Method of use of erythropoietin to treat ischemic acute renal failure
US20060234918A1 (en) 2001-12-19 2006-10-19 Voyager Pharmaceutical Corporation Methods for treating and preventing cancers that express the hypothalamic-pituitary-gonadal axis of hormones and receptors
US20030144203A1 (en) 2001-12-19 2003-07-31 Voyager Pharmaceutical Corporation Methods for slowing senescence and treating and preventing diseases associated with senescence
US6998118B2 (en) 2001-12-21 2006-02-14 The Salk Institute For Biological Studies Targeted retrograde gene delivery for neuronal protection
BR0307548A (pt) 2002-02-11 2006-01-17 Genentech Inc Método de produção de uma variante de anticorpo, variante de anticorpo, composição, ácido nucléico isolado, vetor, célula hospedeira, processo para a produção de uma variante de anticorpo e método de determinação do coeficiente de associação de antìgeno de um anticorpo
AU2003217612A1 (en) 2002-02-21 2003-09-09 Wyeth GASP1: a follistatin domain containing protein
US20030219846A1 (en) 2002-02-28 2003-11-27 Pfizer Inc. Assay for activity of the ActRIIB kinase
WO2003087162A2 (en) 2002-04-18 2003-10-23 Mtm Laboratories Ag Neopeptides and methods useful for detection and treatment of cancer
US20050271637A1 (en) 2002-08-16 2005-12-08 Bodine Peter Van N BMP-2 estrogen responsive element and methods of using the same
US7261893B2 (en) 2002-10-22 2007-08-28 Wyeth Neutralizing antibodies against GDF-8 and uses therefor
US20040223966A1 (en) 2002-10-25 2004-11-11 Wolfman Neil M. ActRIIB fusion polypeptides and uses therefor
AU2002953327A0 (en) 2002-12-12 2003-01-09 Monash University Methods of diagnosing prognosing and treating activin associated diseases and conditions
WO2004069237A1 (en) 2003-02-07 2004-08-19 Prometic Biosciences Inc. Medium-chain length fatty acids, glycerides and analogues as stimulators of erythropoiesis
US20040197828A1 (en) 2003-03-26 2004-10-07 Gaddy Dana P. Method for diagnosis and treatment of bone turnover
WO2005028517A2 (en) 2003-05-09 2005-03-31 The General Hospital Corporation SOLUBLE TGF-β TYPE III RECEPTOR FUSION PROTEINS
KR20060026860A (ko) 2003-06-02 2006-03-24 와이어쓰 신경근 장애의 치료를 위한, 코르티코스테로이드와 조합된미오스타틴 (gdf8) 저해제의 용도
EP1636270B1 (en) 2003-06-16 2016-07-20 UCB Pharma S.A. Antibodies specific for sclerostin and methods for increasing bone mineralization
WO2005009460A2 (en) 2003-07-25 2005-02-03 Medexis, S.A. Pharmaceutical composition comprising activin a, alk-4 or derivatives thereof for the treatment of ophthalmic disorders or cancer
US8895540B2 (en) 2003-11-26 2014-11-25 DePuy Synthes Products, LLC Local intraosseous administration of bone forming agents and anti-resorptive agents, and devices therefor
WO2005070967A2 (en) 2004-01-22 2005-08-04 Merck Patent Gmbh Anti-cancer antibodies with reduced complement fixation
US20050197292A1 (en) 2004-01-30 2005-09-08 Glennda Smithson Compositions and methods for treating T-cell mediated pathological conditions
AU2005229072A1 (en) 2004-03-26 2005-10-13 Acceleron Pharma Inc. BMP-3 propeptides and related methods
CA2561809A1 (en) 2004-03-31 2005-10-20 Xencor, Inc. Bmp-7 variants with improved properties
WO2005113590A2 (en) 2004-05-12 2005-12-01 Acceleron Pharma Inc. Bmp10 propeptides and related methods
EP1771557B1 (en) 2004-06-24 2014-12-31 Acceleron Pharma Inc. GDF3 Propeptides and Related Methods
EP3059245B1 (en) 2004-07-23 2018-11-07 Acceleron Pharma Inc. Actrii receptor antagonistic antibodies
WO2006015368A2 (en) 2004-08-05 2006-02-09 The Regents Of The University Of California Molecules with effects on cellular development and function
US20060034831A1 (en) 2004-08-12 2006-02-16 Wyeth Combination therapy for diabetes, obesity and cardiovascular diseases using GDF-8 inhibitors
CA2581896C (en) 2004-09-29 2015-11-10 Mount Sinai School Of Medicine Of New York University Fsh and fsh receptor modulator compositions and methods for inhibiting osteoclastic bone resorption and bone loss in osteoporosis
CA2587424A1 (en) 2004-11-16 2006-05-26 Avidia Research Institute Protein scaffolds and uses thereof
NL1027887C2 (nl) 2004-12-24 2006-06-27 Bosch Gmbh Robert Transmissie met gebombeerde poelieschijven en een drijfriem.
NZ538097A (en) 2005-02-07 2006-07-28 Ovita Ltd Method and compositions for improving wound healing
EP2954903A1 (en) 2005-02-16 2015-12-16 The General Hospital Corporation Use of bmp antagonists to regulate hepcidin-mediated iron metabolism
WO2006115274A1 (ja) 2005-04-26 2006-11-02 Ajinomoto Co., Inc. 骨髄赤血球前駆細胞分化促進剤
AU2006283532B2 (en) 2005-08-19 2012-04-26 Abbvie Inc. Dual variable domain immunoglobin and uses thereof
JP2007099764A (ja) 2005-09-09 2007-04-19 Ajinomoto Co Inc 血糖低下剤
CA2621623A1 (en) 2005-09-28 2007-04-05 Zymogenetics, Inc. Il-17a and il-17f antagonists and methods of using the same
US8067562B2 (en) 2005-11-01 2011-11-29 Amgen Inc. Isolated nucleic acid molecule comprising the amino acid sequence of SEQ ID NO:1
MX2008006626A (es) * 2005-11-23 2008-09-24 Acceleron Pharma Inc Antagonistas de activin-actriia y usos para promover el crecimiento de huesos.
US8128933B2 (en) 2005-11-23 2012-03-06 Acceleron Pharma, Inc. Method of promoting bone growth by an anti-activin B antibody
CN101370511B (zh) * 2005-11-23 2015-07-01 阿塞勒隆制药公司 Activin-ActRIIa拮抗剂及其促进骨骼生长的应用
MX2008007324A (es) 2005-12-06 2009-03-04 Amgen Inc Usos de antagonistas de miostatina.
AU2006326815A1 (en) 2005-12-20 2007-06-28 Merck Frosst Canada Ltd. Heteroaromatic compounds as inhibitors of stearoyl-coenzyme A delta-9 desaturase
AU2006331770A1 (en) 2005-12-21 2007-07-05 Schering Corporation Treatment of nonalcoholic fatty liver disease using cholesterol lowering agents and H3 receptor antagonist/inverse agonist
WO2007076127A2 (en) 2005-12-22 2007-07-05 Biogen Idec Ma Inc Condensed imidazoles or pyrazoles and their use as transforming growth factor modulators
JP4822562B2 (ja) 2006-01-20 2011-11-24 ベックマン コールター, インコーポレイテッド 低ヘモグロビン濃度細胞百分率および鉄欠乏の検出における使用方法
EP1976377A4 (en) 2006-01-25 2010-06-23 Wellstat Therapeutics Corp COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS
JP2009528375A (ja) 2006-02-28 2009-08-06 ウェルスタット セラピューティクス コーポレイション 代謝障害を処置するための化合物
WO2007120767A2 (en) 2006-04-14 2007-10-25 Amgen Inc. Agonist erythropoietin receptor antibodies
WO2007123391A1 (en) 2006-04-20 2007-11-01 Academisch Ziekenhuis Leiden Therapeutic intervention in a genetic disease in an individual by modifying expression of an aberrantly expressed gene.
AU2007249827A1 (en) 2006-05-09 2007-11-22 Colorado State University Research Foundation Methods for treating blood disorders
CN104095838A (zh) 2006-07-21 2014-10-15 莱因实验室公司 醋酸钙的液体组合物
GB0615129D0 (en) 2006-07-29 2006-09-06 Univ Cardiff Anti-cancer activity of BMP-9 and BMP-10 and their use in cancer therapies
CL2007002567A1 (es) 2006-09-08 2008-02-01 Amgen Inc Proteinas aisladas de enlace a activina a humana.
US7547781B2 (en) 2006-09-11 2009-06-16 Curis, Inc. Quinazoline based EGFR inhibitors containing a zinc binding moiety
WO2008060139A1 (en) 2006-11-17 2008-05-22 Erasmus University Medical Center Rotterdam Methods for controlling mineralization of extracellular matrix, therapeutic methods based thereon and medicaments for use therein
WO2008073292A2 (en) 2006-12-08 2008-06-19 Caritas St. Elizabeth's Medical Center Of Boston, Inc. Method for protecting renal tubular epithelial cells from radiocontrast nephro parhy (rcn)
CA2672581A1 (en) 2006-12-14 2008-06-19 Forerunner Pharma Research Co., Ltd. Anti-claudin 3 monoclonal antibody and treatment and diagnosis of cancer using the same
PL2124999T3 (pl) 2006-12-18 2013-03-29 Acceleron Pharma Inc Antagoniści aktywiny-actrii i zastosowania do leczenia niedokrwistości
US20100028332A1 (en) 2006-12-18 2010-02-04 Acceleron Pharma Inc. Antagonists of actriib and uses for increasing red blood cell levels
US8895016B2 (en) 2006-12-18 2014-11-25 Acceleron Pharma, Inc. Antagonists of activin-actriia and uses for increasing red blood cell levels
WO2008094708A2 (en) 2007-02-01 2008-08-07 Acceleron Pharma Inc. Activin-actriia antagonists and uses for treating or preventing breast cancer
TWI782836B (zh) 2007-02-02 2022-11-01 美商艾瑟勒朗法瑪公司 衍生自ActRIIB的變體與其用途
TWI606062B (zh) 2007-02-09 2017-11-21 艾瑟勒朗法瑪公司 包含ActRIIa-Fc融合蛋白的醫藥組合物;ActRIIa-Fc融合蛋白於治療或預防與癌症相關的骨質流失之用途;ActRIIa-Fc融合蛋白於治療或預防多發性骨髓瘤之用途
TWI573802B (zh) 2007-03-06 2017-03-11 安美基公司 變異之活動素受體多肽及其用途
US8501678B2 (en) 2007-03-06 2013-08-06 Atara Biotherapeutics, Inc. Variant activin receptor polypeptides and uses thereof
CA2685306A1 (en) 2007-06-01 2008-12-11 Wyeth Methods and compositions for modulating bmp-10 activity
WO2009009059A1 (en) 2007-07-09 2009-01-15 Biogen Idec Ma Inc. Spiro compounds as antagonists of tgf-beta
PL2170396T3 (pl) 2007-08-03 2017-07-31 Summit (Oxford) Limited Kombinacje leków do leczenia dystrofii mięśniowej Duchenne'a
GB0715087D0 (en) 2007-08-03 2007-09-12 Summit Corp Plc Drug combinations for the treatment of duchenne muscular dystrophy
GB0715938D0 (en) 2007-08-15 2007-09-26 Vastox Plc Method of treatment of duchenne muscular dystrophy
WO2009025651A1 (en) 2007-08-17 2009-02-26 University Of Maine System Board Of Trustees Biologically active peptide and method of using the same
US20100279409A1 (en) 2007-09-13 2010-11-04 Neil Robson Method for modifying celluar immune resonse by modulating activin activity
WO2009038745A1 (en) 2007-09-18 2009-03-26 Acceleron Pharma Inc. Activin-actriia antagonists and uses for decreasing or inhibiting fsh secretion
PE20091163A1 (es) 2007-11-01 2009-08-09 Wyeth Corp Anticuerpos para gdf8
CA2705879A1 (en) 2007-11-21 2009-06-04 Amgen Inc. Wise binding agents and epitopes
US8507501B2 (en) 2008-03-13 2013-08-13 The Brigham And Women's Hospital, Inc. Inhibitors of the BMP signaling pathway
WO2009137075A1 (en) 2008-05-06 2009-11-12 Acceleron Pharma Inc. Anti-activin antibodies and uses for promoting bone growth
AU2009244308A1 (en) 2008-05-06 2009-11-12 Joslin Diabetes Center, Inc. Methods and compositions for inducing brown adipogenesis
KR20190049912A (ko) 2008-06-26 2019-05-09 악셀레론 파마 인코포레이티드 액티빈-actriia의 길항물질 및 적혈구 수준을 증가시키기 위한 이들의 용도
CA2729096C (en) 2008-06-26 2020-04-28 Acceleron Pharma Inc. Methods for dosing an actriib antagonist and monitoring of treated patients
HRP20191109T1 (hr) 2008-08-14 2019-09-20 Acceleron Pharma Inc. Gdf klopke za uporabu u liječenju anemije
US8216997B2 (en) 2008-08-14 2012-07-10 Acceleron Pharma, Inc. Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators
WO2010059861A1 (en) 2008-11-20 2010-05-27 University Of Southern California Compositions and methods to modulate hair growth
LT2370463T (lt) 2008-11-26 2016-12-12 Amgen Inc. Stabilizuotas aktivino iib receptoriaus variantas
WO2010083034A1 (en) 2009-01-13 2010-07-22 Acceleron Pharma Inc. Methods for increasing adiponectin
US8110355B2 (en) 2009-02-20 2012-02-07 GenRemedy, LLC Methods for identifying agents that inhibit cell migration, promote cell adhesion and prevent metastasis
SG174273A1 (en) 2009-04-27 2011-10-28 Novartis Ag Compositions and methods for increasing muscle growth
AU2010258931B2 (en) 2009-06-08 2015-04-23 Acceleron Pharma Inc. Methods for increasing thermogenic adipocytes
CN107267520A (zh) 2009-06-12 2017-10-20 阿塞勒隆制药公司 截短的actriib‑fc融合蛋白
KR101882521B1 (ko) 2009-08-13 2018-07-27 악셀레론 파마 인코포레이티드 적혈구 수준을 증가시키기 위한 gdf 트랩과 에리트로포이에틴 수용체 활성인자의 병용
ES2869580T3 (es) 2009-09-09 2021-10-25 Acceleron Pharma Inc Antagonistas de ActRIIB y dosificación y usos de los mismos para tratar obesidad o diabetes tipo 2 regulando el contenido de grasa corporal
EP3260130B1 (en) 2009-11-03 2021-03-10 Acceleron Pharma Inc. Methods for treating fatty liver disease
CA2781152A1 (en) 2009-11-17 2011-05-26 Acceleron Pharma Inc. Actriib proteins and variants and uses therefore relating to utrophin induction for muscular dystrophy therapy
WO2012027065A2 (en) 2010-08-27 2012-03-01 Celgene Corporation Combination therapy for treatment of disease
US8580922B2 (en) 2011-03-04 2013-11-12 Shire Human Genetic Therapies, Inc. Peptide linkers for polypeptide compositions and methods for using same
WO2013006437A1 (en) 2011-07-01 2013-01-10 Novartis Ag Method for treating metabolic disorders
EA202090053A3 (ru) 2011-10-17 2020-06-30 Акселерон Фарма, Инк. Способы и композиции для лечения неэффективного эритропоэза
WO2013063536A1 (en) 2011-10-27 2013-05-02 Acceleron Pharma, Inc. Actriib binding agents and uses thereof
US8765385B2 (en) 2011-10-27 2014-07-01 Ravindra Kumar Method of detection of neutralizing anti-actriib antibodies
EP2793925B1 (en) 2011-12-19 2019-03-20 Amgen Inc. Variant activin receptor polypeptides, alone or in combination with chemotherapy, and uses thereof
US9878056B2 (en) 2012-04-02 2018-01-30 Modernatx, Inc. Modified polynucleotides for the production of cosmetic proteins and peptides
US9102212B2 (en) 2012-05-14 2015-08-11 Paccar Inc Fresh air system for heavy duty vehicle cab/sleeper combination
WO2013186777A2 (en) 2012-06-14 2013-12-19 The Medical Researth, Infrastructure, And Health Services Fund Of The Tel Aviv Medical Center Use of blocking agents of bone morphogenie protein (bmp) signaling for the treatment of neuroinflammatory and neurodegenerative diseases
CA2874117C (en) 2012-07-02 2021-10-12 Kyowa Hakko Kirin Co., Ltd. Pharmaceutical agent comprising anti-bmp9 antibody as active ingredient for treatment of anemia such as renal anemia and cancer anemia
AU2013334660B2 (en) 2012-10-24 2018-08-09 Celgene Corporation Methods for treating anemia
IL290653B2 (en) 2012-10-24 2025-05-01 Celgene Corp Biomarker for use in the treatment of anemia
WO2014064292A1 (en) 2012-10-26 2014-05-01 Universite Pierre Et Marie Curie (Paris 6) A method for preventing or treating atrial fibrillation
ES2884095T3 (es) 2012-11-02 2021-12-10 Celgene Corp Antagonistas de activina-actrii y usos para el tratamiento de trastornos óseos y otros trastornos
EA034963B1 (ru) 2012-11-08 2020-04-13 Клиасайд Байомедикал, Инк. Способ лечения расстройства заднего сегмента глаза
US20150328249A1 (en) 2012-12-11 2015-11-19 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Modulation of myofiber repair by anti-myostatin strategies and/or ppar gamma ligands, alone or in combination with stem cells, for the therapy of critical limb ischemia and other ischemic processes affecting the skeletal muscle
US20140220033A1 (en) 2013-02-01 2014-08-07 Santa Maria Biotherapeutics, Inc. Administration of an Anti-Activin-A Compound to a Subject
US20160184458A1 (en) 2013-03-14 2016-06-30 Shire Human Genetic Therapies, Inc. Mrna therapeutic compositions and use to treat diseases and disorders
TWI655207B (zh) 2013-07-30 2019-04-01 再生元醫藥公司 抗活化素a之抗體及其用途
US20160200818A1 (en) 2013-08-14 2016-07-14 Novartis Ag Methods of treating Sporadic Inclusion Body Myositis
WO2015089575A1 (en) 2013-12-16 2015-06-25 Paranta Biosciences Limited Method of diagnosis and treatment
EP3094751A4 (en) 2014-01-14 2017-06-07 Santa Maria Biotherapeutics, Inc. Activin inhibitor response prediction and uses for treatment
CN105992951A (zh) 2014-01-27 2016-10-05 诺华股份有限公司 预测肌萎缩的生物标志物、方法和用途
US10260068B2 (en) 2014-03-31 2019-04-16 Sumitomo Dainippon Pharma Co., Ltd. Prophylactic agent and therapeutic agent for fibrodysplasia ossificans progressiva
TW201622746A (zh) 2014-04-24 2016-07-01 諾華公司 改善或加速髖部骨折術後身體復原之方法
CA2952231A1 (en) 2014-06-13 2015-12-17 Santa Maria Biotherapeutics, Inc. Formulated receptor polypeptides and related methods

Similar Documents

Publication Publication Date Title
JP2010518006A5 (OSRAM)
JP2010518079A5 (OSRAM)
RU2009132663A (ru) АНТАГОНИСТЫ АКТИВИНА-ActRIIa И ИХ ПРИМЕНЕНИЕ ДЛЯ ЛЕЧЕНИЯ ИЛИ ПРОФИЛАКТИКИ РАКА МОЛОЧНОЙ ЖЕЛЕЗЫ
JP2013504589A5 (OSRAM)
JP2010513506A5 (OSRAM)
JP2011530599A5 (OSRAM)
JP2010539236A5 (OSRAM)
JP2014500278A (ja) 二重特異性scFvコンジュゲートの投薬量および投与
US20230331858A1 (en) Combination therapy using an il-2 receptor agonist and an immune checkpoint inhibitor
CN111315398A (zh) 白介素-10与免疫检查点途径抑制剂的组合的组合物和使用方法
CN111343984A (zh) 包含链黑菌素及雷帕霉素作为有效成分的癌症预防或治疗用药学组合物
US9068016B2 (en) Conjugates for the treatment of mesothelioma
US8183201B2 (en) Methods of treating αvβ3 integrin-associated diseases by administering polypeptides selective for αvβ3 integrin
WO2015138638A1 (en) Long acting trail receptor agonists for treatment of autoimmune diseases
ES2186596T3 (es) Uso de inhibidores de la interleucina-18 para inhibir metastasis tumorales.
JP2020501513A (ja) 治療用多標的コンストラクトおよびその使用
JP2007536891A (ja) 抗癌作用を有する組換えタンパク質、それをコードする遺伝子、及びそれらの使用
AU2006278229B2 (en) Methods for treating B-cell malignancies using TACI-Ig fusion molecule
JP2011102322A (ja) 毒性が低下したtnfファミリーのリガンド、リガンドのアゴニストの投与方法
CN111788217A (zh) 白介素-15活性的拮抗剂肽
JP5597534B2 (ja) 抗腫瘍性の薬物、医薬、組成物、およびその使用
KR101824205B1 (ko) 암 예방 또는 치료용 약학적 조성물 및 이의 용도
JP7522770B2 (ja) 術後補助療法剤
EP2716297B1 (en) D-glu-fniii14 polypeptide for use in treating cancer
CN111732631B (zh) 一种多肽及其在制备治疗和预防肿瘤的药物中的应用